Compare FMC Corp (FMC) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Gilead Sciences, Inc. — how do they compare? FMC Corp trades at $10.5 (market cap $1.30B), while Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 129.5× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| FMC | GILD | |
|---|---|---|
Market Cap | $1.30B | $168.35B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $155.80 |
52-Week Low | $10.01 | $110.56 |
Enterprise Value | $5.11B | $191.42B |
Dividend Yield | 3.07% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
